A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

NCT00569192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: 0.135mg MAP0010
DRUG: 0.25mg MAP0010
DRUG: Placebo

Sponsor

Allergan

Collaborators

[object Object]